Table 3.
Remission rate in each group by DAS28-ESR, CDAI, and SDAI
| Remission rate | PWs or HWs | TCZ-SC group, n (%) | csDMARDs-alone group, n (%) | Odds ratio for TCZ-SC group/csDMARDs-alone group (95% confidence interval) |
P value (TCZ-SC group vs csDMARDs-alone group) |
|---|---|---|---|---|---|
| DAS28-ESR | Overall | 205.0 (67.9) | 64.6 (21.7) | 6.778 (4.508, 10.189) | < 0.0001 |
| PWs | 104.1 (66.3) | 39.7 (25.5) | 5.689 (3.146, 10.287) | < 0.0001 | |
| HWs | 102.0 (70.3) | 22.8 (16.1) | 9.153 (4.814, 17.403) | < 0.0001 | |
| CDAI | Overall | 125.5 (39.2) | 58.5 (19.2) | 2.549 (1.631, 3.982) | < 0.0001 |
| PWs | 62.4 (37.3) | 43.0 (27.1) | 1.564 (0.860, 2.845) | 0.1427 | |
| HWs | 70.2 (45.9) | 16.1 (11.1) | 5.635 (2.757, 11.516) | < 0.0001 | |
| SDAI | Overall | 132.1 (41.8) | 57.4 (19.1) | 2.855 (1.828, 4.458) | < 0.0001 |
| PWs | 65.8 (40.1) | 41.6 (26.5) | 1.811 (0.991, 3.309) | 0.0535 | |
| HWs | 73.0 (48.1) | 16.1 (11.3) | 6.052 (2.981, 12.288) | < 0.0001 |
Adjusted odds ratio by the logistic regression model using last observation carried forward; adjusted-weight analysis by inverse probability treatment weighting method
Remission was defined as DAS28-ESR < 2.6, CDAI ≤2.8, and SDAI ≤3.3
CDAI clinical disease activity index, csDMARD conventional synthetic disease-modifying antirheumatic drug, DAS28-ESR disease activity score in 28 joints using the erythrocyte sedimentation rate, HW house worker, PW paid worker, SDAI simplified disease activity index, TCZ-SC tocilizumab by subcutaneous injection